Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study.

Okamoto H, Hori M, Matsuzaki M, Tsutsui H, Yamazaki T, Nagai R, Yoshikawa T, Fujio Y, Nonen S, Azuma J, Izumi T, Ohashi Y, Kitabatake A; J-CHF Investigators.

Int J Cardiol. 2013 Apr 5;164(2):238-44. doi: 10.1016/j.ijcard.2012.11.051. Epub 2012 Dec 12.

PMID:
23245621
[PubMed - indexed for MEDLINE]
Free Article
2.

Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.

Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S; MUCHA Investigators.

Am Heart J. 2004 Feb;147(2):324-30.

PMID:
14760332
[PubMed - indexed for MEDLINE]
3.

[Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure].

Kawashiro N, Matsuda N, Endo Y, Uchida Y, Kasanuki H.

J Cardiol. 2006 May;47(5):229-37. Japanese.

PMID:
16764329
[PubMed - indexed for MEDLINE]
4.

Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.

Fujimura M, Akaike M, Iwase T, Yoshida S, Sumitomo Y, Yagi S, Ikeda Y, Hashizume S, Aihara K, Nishiuchi T, Yasumura Y, Matsumoto T.

Acta Cardiol. 2009 Oct;64(5):589-95.

PMID:
20058503
[PubMed - indexed for MEDLINE]
5.

Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.

Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M; Carvedilol Prospective Randomized Cumulative Survival Study Group.

J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9.

PMID:
15093878
[PubMed - indexed for MEDLINE]
Free Article
6.

Carvedilol: a review of its use in chronic heart failure.

Keating GM, Jarvis B.

Drugs. 2003;63(16):1697-741. Review.

PMID:
12904089
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.

Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK.

Circ Heart Fail. 2011 Jan;4(1):18-26. doi: 10.1161/CIRCHEARTFAILURE.109.932558. Epub 2010 Oct 29.

PMID:
21036889
[PubMed - indexed for MEDLINE]
Free Article
8.

The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a prospective, randomized-controlled study.

Huang M, Zhang X, Chen S, Sun Y, Xiao Y, Sun J, Huang M, Chen S, Liu F.

Pediatr Cardiol. 2013 Mar;34(3):680-5. doi: 10.1007/s00246-012-0527-x. Epub 2012 Oct 30.

PMID:
23108482
[PubMed - indexed for MEDLINE]
9.

Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).

Di Lenarda A, Remme WJ, Charlesworth A, Cleland JG, Lutiger B, Metra M, Komajda M, Torp-Pedersen C, Scherhag A, Swedberg K, Poole-Wilson PA; COMET investors.

Eur J Heart Fail. 2005 Jun;7(4):640-9.

PMID:
15921806
[PubMed - indexed for MEDLINE]
10.

Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.

Susa T, Kobayashi S, Tanaka T, Murakami W, Akashi S, Kunitsugu I, Okuda S, Doi M, Wada Y, Nao T, Yamada J, Ueyama T, Okamura T, Yano M, Matsuzaki M.

Circ J. 2012;76(1):117-26. Epub 2011 Oct 19.

PMID:
22008315
[PubMed - indexed for MEDLINE]
Free Article
11.

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

Circulation. 2002 Oct 22;106(17):2194-9.

PMID:
12390947
[PubMed - indexed for MEDLINE]
Free Article
12.

Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.

Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, Caporotondi A, Mortara A, Pinna GD, Cobelli F.

Am Heart J. 2000 Apr;139(4):596-608.

PMID:
10740140
[PubMed - indexed for MEDLINE]
13.

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA.

J Card Fail. 1997 Sep;3(3):173-9.

PMID:
9330125
[PubMed - indexed for MEDLINE]
14.

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N.

Circulation. 1996 Dec 1;94(11):2807-16.

PMID:
8941106
[PubMed - indexed for MEDLINE]
Free Article
15.

The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure.

Yildirir A, Sade E, Tokgozoglu L, Oto A.

Eur J Heart Fail. 2001 Dec;3(6):717-21.

PMID:
11738224
[PubMed - indexed for MEDLINE]
16.

Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure.

Castro P, Vukasovic JL, Chiong M, Díaz-Araya G, Alcaino H, Copaja M, Valenzuela R, Greig D, Pérez O, Corbalan R, Lavandero S.

Eur J Heart Fail. 2005 Oct;7(6):1033-9.

PMID:
16227141
[PubMed - indexed for MEDLINE]
17.

Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ; CARMEN investigators and co-ordinators.

Eur J Heart Fail. 2004 Jun;6(4):467-75.

PMID:
15182773
[PubMed - indexed for MEDLINE]
18.

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH.

N Engl J Med. 1996 May 23;334(21):1349-55.

PMID:
8614419
[PubMed - indexed for MEDLINE]
Free Article
19.

Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.

Mortara A, La Rovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F.

J Am Coll Cardiol. 2000 Nov 1;36(5):1612-8.

PMID:
11079666
[PubMed - indexed for MEDLINE]
Free Article
20.

Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.

Razzolini R, Tarantini G, Boffa GM, Orlando S, Iliceto S.

Ital Heart J. 2004 Jul;5(7):517-22.

PMID:
15487269
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk